cancer

Big Pharma Looks Beyond Drugs to Smartphone Apps

Pharmaceutical companies looking for fresh sources of profit are increasingly investing in a range of health care innovations that aren't drugs at all, from smartphone apps and educational websites to social media platforms and wireless devices, reports Ernst & Young.

Two Drugs Found to Fight Steve Jobs' Rare Cancer Type

Pfizer's cancer drug Sutent and Novartis's drug Afinitor have both been found to be effective against the rare form of pancreatic cancer that Apple CEO Steve Jobs was diagnosed with in 2004, according to two studies published in the New England Journal of Medicine.

Another Cancer-Drug Failure Highlights Difficulties Facing Pharmas

Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the patent cliff, when they will be forced to compete with cheaper generics.

What Pfizer Sees in Lpath's Innovative Blindness Drugs

Lpath focuses on developing therapeutics that target bioactive lipids for treating a range of human diseases, including cancer and diseases that cause blindness. Its promising drugs have attracted attention -- and lots of money -- from Pfizer. More of both could be coming.

A Judge Snuffs Out New York City's Gruesome Antismoking Ads

A New York City health code regulation set to go into effect on Jan. 1 would have added some disturbing images to the Big Apple's glittering background of advertising: Hideously accurate ads depicting the results of smoking. But a federal judge this week killed the city's anti-smoking campaign before it could begin.

Genzyme Talks Up Possible Sales of Its New MS Drug

Biotechnology company Genzyme is holding an analyst and investor meeting Monday focused on the commercial potential of its multiple sclerosis drug Campath as it tries to convince Sanofi-Aventis that it's worth more than the Paris-based pharmaceutical giant has been offering.

Wyeth Loses Appeal Over Hormone Replacement Drugs

Wyeth Pharmecuticals on Wednesday lost its appeal of a decision that awarded $58 million in damages to three women who claimed the company's hormone-replacement drugs caused their breast cancer.

Are 'Green' Cleaners Really Green?

green policeSupposedly "green" cleaners may not be as green as you think. You're probably being exposed to chemicals even if you're using presumably eco-friendly...

AIG Says CEO Benmosche Has Cancer

AIG (AIG) said that CEO Robert Benmosche has cancer and is undergoing aggressive chemotherapy. "The good news is that I feel fine, and I continue to work according to my normal schedule," Benmosche said in a statement. "I remain absolutely committed to my job, to AIG, and to all of our stakeholders."

The Allure of Delcath's Highly Targeted Chemotherapy

Traditional chemotherapy for cancer patients is as dreaded as the disease itself. But Delcath's "Chemosaturation System," which is doing well so far in tests, promises to deliver treatments far more precisely, thus limiting side effects.

Is This Tiny Aussie Biotech the Next Dendreon?

Dendreon's Provenge, which targets prostate cancer, catapulted that company's stock to record highs recently. Prima Biomed's CVac works similarly, but it has the potential to target multiple forms of cancer, giving the Australian company an intriguing future.

Roche Strikes $1.1 Billion Deal With Aileron

Swiss pharmaceutical giant Roche has struck a deal with Aileron Therapeutics worth up to $1.1 billion to gain access to a new class of drugs called stapled peptide therapeutics. This could yield new ways to attack hard-to-reach disease targets.

'Fructose-Slurping' Cancer Could Sour the Soda Business

Soda and processed-food makers insist that all sugars are the same. Yet with studies linking high fructose corn syrup to obesity, diabetes and, most recently, pancreatic cancer, big brands are quietly backing away from using the corn-based sweetener.

Philip Morris Earnings Gain on Prices, Currency Exchange Rates

Philip Morris International Inc. (PM) reported earnings of $1.07 per diluted share, a 35.4% increase from the second quarter of 2009. Second quarter revenue rose 15.1% to $7.061 billion, driven by rising prices and favorable currency exchange rates, the company said in a statement. Net revenue rose in each of the company%u2019s markets. The biggest gain was in Asia, which saw net revenue jump 35% to $ 2.123 billion.

Will FDA Withdraw Avastin Approval for Breast Cancer?

Roche's blockbuster cancer drug, Avastin, could lose its U.S. Food and Drug Administration approval for use against breast cancer after an FDA panel recommended the withdrawal. Studies failed to show the drug extends breast-cancer patients' lives, panelists say.

Daily Blogwatch: Why the S&P Will Rise to 1,500

Some of the best reads for investors from around the Web, including posts about why the Standard & Poor's 500 is on its way up, why Warren Buffett's bullish on Tesco, why drug company Dendreon fell 20% in after-hours trading, and why a hamburger is called a hamburger.

Celgene to Buy Abraxis for $2.9 Billion

Biotechnology company Celgene (CELG) announced it is buying Abraxis BioScience (ABII) for $2.9 billion in cash and stock. With this acquisition, Ceglene is expanding its portfolio of cancer treatments.

Coffee, the new health food?

Coffee, the new health food?You know it gives you a morning buzz and makes that wait in the Starbucks line worth it. But here's something you may not have realized about coffee:...

Blood Pressure Drugs Linked to Higher Cancer Rate

Angiotensin-receptor blockers, a common class of blood pressure medications, have been linked to an increased risk of cancer in a recent study. These widely used drugs include medicines such as Boehringer's Micardis, Merck's Cozaar and Hyzaar, and Novartis's Diovan.